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Hyperphosphorylation of protein tau is a hallmark of Alzheimer’s disease (AD).
Changes in energy and lipid metabolism have been correlated with the late onset
of this neurological disorder. However, it is uncertain if metabolic dysregulation is
a consequence of AD or one of the initiating factors of AD pathophysiology. Also,
it is unclear whether variations in lipid metabolism regulate the phosphorylation
state of tau. Here, we show that in humanized yeast, tau hyperphosphorylation is
stimulated by glucose starvation in coincidence with the downregulation of Pho85,
the yeast ortholog of CDK5. Changes in inositol phosphate (IP) signaling, which has
a central role in energy metabolism, altered tau phosphorylation. Lack of inositol
hexakisphosphate kinases Kcs1 and Vip1 (IP6 and IP7 kinases in mammals) increased
tau hyperphosphorylation. Similar effects were found by mutation of IPK2 (inositol
polyphosphate multikinase), or PLC1, the yeast phospholipase C gene. These effects
may be explained by IP-mediated regulation of Pho85. Indeed, this appeared to be
the case for plc1, ipk2, and kcs1. However, the effects of Vip1 on tau phosphorylation
were independent of the presence of Pho85, suggesting additional mechanisms.
Interestingly, kcs1 and vip1 strains, like pho85, displayed dysregulated sphingolipid
(SL) metabolism. Moreover, genetic and pharmacological inhibition of SL biosynthesis
stimulated the appearance of hyperphosphorylated forms of tau, while increased flux
through the pathway reduced its abundance. Finally, we demonstrated that Sit4, the
yeast ortholog of human PP2A protein phosphatase, is a downstream effector of SL
signaling in mediating the tau phosphorylation state. Altogether, our results add new
knowledge on the molecular effectors involved in tauopathies and identify new targets
for pharmacological intervention.
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INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neuro-
degenerative disease being responsible for 60–70% of the
50 million cases of dementia every year (Prince et al., 2015).
Current treatments for AD remain supportive, without changing
the life expectancy or overall progression of dementia (Weller
and Budson, 2018). Accordingly, understanding the molecular
mechanisms that finally result in this neurodegenerative disorder
has been and remains of major importance.
The neurodegenerative process in AD is characterized by the
progressive accumulation of amyloid plaques, mainly composed
of amyloid-beta peptides (Aβ), and neurofibrillary tangles
(NFTs) composed of hyperphosphorylated tau (Jeong, 2017).
The amyloid plaques accumulate extracellularly in the brains
of AD patients and are generated by sequential processing
of the amyloid precursor protein, APP (Glenner et al., 1984;
Dyrks et al., 1988). The neurofibrillary tangles are found inside
neurons and consist of an abnormally phosphorylated form of
the tau protein (Buée et al., 2000). Although Aβ and tau exert
their neurotoxic effects through separate mechanisms (Grimm
and Hartmann, 2012), several studies suggest that tau is an
essential executor of β-amyloid neurotoxicity (Rapoport et al.,
2002; Roberson et al., 2007; Ittner et al., 2010). Thus, reducing
self-assembled hyperphosphorylated tau might be pivotal to
alleviate tau deposition and confer resistance to Aβ-mediated
neurodegeneration.
The tau protein belongs to the family of microtubule (MT)-
associated proteins (MAPs) (Weingarten et al., 1975). As a
result of alternative splicing, six major isoforms are present in
human brain (Ksiezak-Reding et al., 1988), which in turn, exhibit
different post-translational modifications. Phosphorylation of
tau is the most prevalent, occurring in up to 85 amino acid
residues (Grimm and Hartmann, 2012; Šimić et al., 2016),
and these modification impact on the MT-stabilizing properties
of tau (Lindwall and Cole, 1984). In particular, the aberrant
phosphorylation (hyperphosphorylation) on several residues
(e.g., Thr31, Thr181, Ser202, Ser205, Ser214, Ser296, Ser404, Ser409,
and Ser422) severely affects tau’s binding capacity to MT
(Šimić et al., 2016).
Several protein kinases, including glycogen synthase kinase
GSK3β (Baum et al., 1996; Lucas et al., 2001) and the cyclin-
dependent kinase CDK5 (Cruz et al., 2003, 2006; Zheng
et al., 2005) are involved in tau phosphorylation (Grimm
and Hartmann, 2012; Šimić et al., 2016). Studies have also
identified serine/threonine protein phosphatases, in particular
PP1 and PP2A, as being important for tau dephosphorylation
in mammalian cells (Hernández et al., 2010). CDK5 acts as
a modulator of tau hyperphosphorylation via the inhibitory
regulation of GSK3β (Plattner et al., 2006; Chow et al., 2014).
Furthermore, activated CDK5 promotes tau phosphorylation
by inactivating PP1 (Lu et al., 2011). Remarkably, evidence
also exists that tau phosphorylation responds to a sequential
mechanism, and that tau phosphorylation by GSK3β may favor
phosphoepitopes affected by other kinases (Zheng-Fischhöfer
et al., 1998). Thus, abnormal increased CDK5 activity contributes
to the neurodegenerative process directly and indirectly.
However, the mechanisms and effectors involved in regulating
CDK5 remain unclear.
It is well established that metabolic dysfunctions contribute
to the risk and pathophysiology of neurodegenerative diseases,
including the AD (Isacson et al., 2019). Biochemical evidence has
established a link between Aβ formation, neuronal death, and
alterations in the sphingolipid (SL) metabolism (Alaamery et al.,
2020; Crivelli et al., 2020). Plasma SLs have been proposed as
diagnostic and prognostic biomarkers of AD (Han et al., 2011)
based on the idea of a link between SL changes and progression
of cognitive decline in AD patients (Mielke and Haughey, 2012;
Couttas et al., 2014). Increased levels of ceramides, triggered
by upregulation of ceramide synthase- and sphingomyelinase-
encoding genes (Katsel et al., 2007; He et al., 2010) and lower
contents of sphingomyelin and sphingosine-1-phosphate (S1P),
have been found in AD patients (Han et al., 2002; He et al.,
2010; Filippov et al., 2012; van Echten-Deckert and Walter, 2012;
Couttas et al., 2014). Alterations in ceramide levels have been
postulated to contribute to the apoptotic signaling and favor
Aβ formation (Hernández-Corbacho et al., 2017), while low S1P
levels would result in a reduction of neuroprotective signals
(Moruno-Manchon et al., 2015). However, the discrepancies
between different studies on changes in SL metabolism in AD
are remarkable (Crivelli et al., 2020). Intriguingly, studies on
sphingosine-kinase and sphingosine-degrading enzymes have
shown that lowering S1P decreases the Aβ production in vitro and
in vivo (Takasugi et al., 2011; Karaca et al., 2014; Lei et al., 2019).
In addition, the relation between tau and the SL metabolism is
poorly characterized, and there is no evidence of the implication
of these lipids in its regulation.
The Pho80-Pho85 cyclin/cyclin-dependent kinase (CDK)
complex is a key component of the phosphate (PHO) signaling
response in yeast (Lee et al., 2008). In addition, Pho85, the
Saccharomyces cerevisiae ortholog of CDK5 (Nishizawa et al.,
1999), can bind different cyclins and as such has a pleiotropic
role on several aspects of the yeast metabolism (Conrad
et al., 2014), including SL biosynthesis. Pho85 modulates the
abundance of Ypk1 and Orm2 proteins (Prieto et al., 2020),
the regulatory circuit that controls the synthesis of long-
chain bases (LCBs) (Liu et al., 2012; Gururaj et al., 2013;
Teixeira and Costa, 2016; Roelants et al., 2017), which are
the direct precursors of ceramides and complex yeast SLs
(Megyeri et al., 2016). Pho85 functions in the phosphorylation
and degradation of Lcb4, the major LCB kinase (Iwaki et al.,
2005) that plays a role in regulating the steady-state level of
yeast-phosphorylated LCBs (LCBPs), i.e., dihydrosphingosine-1-
phosphate (DhS1P) and phytosphingosine-1-phosphate (PhS1P).
Thus, changes in SL species could mediate the signaling activity
of Pho85 and determine the functionality of downstream
effectors. Whether such regulatory links exist for CDK5 to
control the phosphorylation state of tau in mammalian cells is
an open question.
Pho85 is a key element in connecting phosphate metabolism
and SL synthesis. When yeast cells are starved of inorganic
phosphate, the Pho80-Pho85 cyclin-CDK complex is inactivated
by the reversible binding of the diphosphoinositol phosphate
(DPIP) 1-IP7 which leads to the subsequent transcription of
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PHO genes (Lee et al., 2007, 2008). Likewise, changes in DPIP
levels caused by membrane stress, i.e., cold shock, inhibit Pho85
activity leading to a significant change in the levels of LCBs
and LCBPs (Prieto et al., 2020). DPIPs, also known as inositol
pyrophosphates (Wundenberg and Mayr, 2012), are produced
by the sequential action of inositol multiphosphate kinases,
Ipk2 and Ipk1, which transform the precursor myo-D-inositol
1, 4, 5-trisphosphate (IP3) in myo-inositol 1, 2, 3, 4, 5, 6-
hexakisphosphate (IP6). Then, IP6 is converted into the DPIP
1-IP7 or 5-IP7 by the action of two IP6 kinases, Vip1 (1PP-
IP5 kinase or IP7 kinase in mammals) and Kcs1 (5PP-IP5 or
IP6 kinase in mammals) (Dubois et al., 2002; Mulugu et al.,
2007; Lin et al., 2009; Wilson et al., 2013). Interestingly, a loss
of inositol polyphosphate multikinase (IPMK) activity has been
reported in the striatum of Huntington’s disease (HD) patients
and in several cellular and animal models of the disease (Ahmed
et al., 2015). Moreover, a link between increased production of
1-IP7 and AD has been proposed by tagging single nucleotide
polymorphism (SNP) analysis of the IP6K3 gene, one of the three
mammalian alleles encoding IP6 kinases, in patients with familial
and sporadic late-onset Alzheimer’s disease (LOAD) (Crocco
et al., 2016). Nevertheless, the relevance of DPIPs in the context
of AD and whether their function is mediated by CDKs need
to be addressed.
In this paper, we have taken advantage of the use of
humanized yeast to examine the role of IPs and SLs in
regulating the phosphorylation state of human tau. Different
studies have demonstrated that the budding yeast S. cerevisiae
is a useful model system for functional studies of human
proteins, including those involved in neurodegenerative diseases
that do not have a homolog in yeast (Winderickx et al., 2008;
Verduyckt et al., 2016; Fruhmann et al., 2017; Tenreiro et al.,
2017). More importantly, yeast model of AD recapitulates
robustly different important aspects of the tau pathobiology
associated with AD pathology, including hyperphosphorylation
and aggregation of human tau in a Pho85-dependent manner
(Vandebroek et al., 2005, 2006). Finally, yeasts and human cells
share most fundamental features of eukaryotic cell biology,
and thus, yeast models allow to carrying a screen of an entire
genome for discovering mechanisms and effectors involved in
protein-misfolding pathologies (Treusch et al., 2011). Our results
provide evidence by genetic and pharmacological inhibition of
IP and SL pathways that these lipid molecules are implicated
in modulating the phosphorylation of tau via Pho85, thereby
connecting different lipid signaling pathways to the control of the
hallmark protein of tauopathies.
MATERIALS AND METHODS
Strains, Plasmids, Media, and Culture
Conditions
The yeast strains, plasmids, and oligonucleotides used in this
study are listed in Supplementary Tables S1–S3, respectively.
LCB4 and LCB5 deletions were carried out by PCR-based gene
disruption using plasmid pAG32 (Goldstein and McCusker,
1999) as a template and the appropriate target-gene-specific
oligonucleotide pairs (Supplementary Table S2). Pho85 and
Pho81 C-terminal tagging with the 13xMyc or 3xHA epitopes
was carried out by PCR-based gene tagging using plasmids
pFA6a-13Myc-His3MX6 or pFA6a-3HA-His3MX6, respectively
(Longtine et al., 1998). Previously described standard methods
were used for YPD and SD media preparation (Guthrie and Fink,
1991). SCD contained 2% glucose as a carbon source and the
appropriate amino acid dropout mixture (Formedium, England).
For drug treatments, phytosphingosine (PhS) (Cayman, Ann
Arbor, MI), myriocin (Myr) (Cayman, Ann Arbor, MI), or
aureobasidin A (AbA) (Takara, Mountain View, CA) were added
to cells grown to the mid-log phase (Abs600 ∼0.5) at 25,
2, or 0.068 µM, respectively, and cultures were maintained
under shaking at 30◦C for 30 min (PhS) or 1 h (Myr and
AbA). Stock solutions of 25 mM PhS (methanol), 2 mM Myr
(ethanol:DMSO, 80:20, v:v), and 90 mM AbA (ethanol), were
prepared, sampled in small volumes, and stored at −20◦C until
use at the indicated concentrations.
For plate phenotype experiments, cells were grown to the
mid-exponential phase at 30◦C (Abs600 ∼0.5). Then, 10-fold
serial dilutions were prepared and 3 µl aliquots of each sample
(1–10−3) were applied over the agar-gelled plates. Colony
growth was inspected after 2–4 days of incubation at 30◦C.
In some experiments, the growth of yeast transformants was
followed in liquid medium by using a POLARstar Omega
microplate reader (BMG LABTECH, Germany). For this, 30◦C-
grown saturated SCD-Ura cultures were diluted in the same
medium at initial OD600 ∼0.05 and microplate wells were filled
with 200 µl. All assays were performed in triplicate at 30◦C
for 24 h. The growth of yeast mutants in YPD lacking or
containing 0.034 or 0.068 µM AbA was followed under the
same conditions.
To evaluate the effects of glucose concentration on tau
phosphorylation, yeast cells were grown on SCD-Ura to the
mid-exponential phase at 30◦C (Abs600 ∼0.3). At this time,
an aliquot of the culture was processed (C0) and the rest
was centrifuged. Cells were washed twice in sterile cold water,
resuspended in fresh SCD-Ura medium (control culture) or
in the same medium containing 0.01% glucose as sole carbon
source, and cultured under shaking conditions at 30◦C, and
aliquots were withdrawn after 1–3 h. In all cases, cells were seeded
by centrifugation and washed and the pellet of cells were kept at
−80◦C until use.
Preparation of Protein Extracts and
Western Blot Analysis
Protein extracts were prepared and proteins were separated
by SDS-PAGE and analyzed by a Western blot as formerly
described (Córcoles-Sáez et al., 2016). Recombinant tau and
phosphorylated (S396/S404) tau were detected using mouse
monoclonal antibodies Tau5 (1:2,000, cat# sc-58,860; Santa Cruz
Biotechnology, Santa Cruz, CA) and AD2 (1:2,000, mAb# 56,484;
Bio-Rad Laboratories, Inc., Hercules, CA), respectively. Rabbit
polyclonal antibody PG5 (1:1,000, cat# 44-760G; Invitrogen,
Camarillo, CA) was used to detect the phospho-S409 epitope.
The proteins tagged with 3xHA (Pho81-HA) and 13xMyc
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(Pho85-Myc) were visualized with anti-HA (1:2,000, cat# sc-
7,392; Santa Cruz Biotechnology) and anti-Myc (1:2,000, cat#
sc-40; Santa Cruz Biotechnology) mouse monoclonal antibodies,
respectively. Mouse monoclonal anti-Pgk1 (C-terminal; 1:3,000,
cat# SAB1402307; Merck KGaA, Darmstadt, Germany) and
anti-G6Pdh antibodies (1:3,000; cat# sc-47724; Santa Cruz
Biotechnology) were used to detect phosphoglycerate kinase
1 and glucose-6-phosphate dehydrogenase as loading control,
respectively. Horseradish peroxidase-conjugated goat anti-rabbit
(1:2,000, cat# 7,074; Cell Signaling, Danvers, MA, United States)
or rabbit anti-mouse (1:5,000, cat# P0260; Dako, Carpinteria,
CA) were used as secondary antibodies. Blots were done as
described elsewhere (Córcoles-Sáez et al., 2016). Imaging of
chemiluminescent Western blots was carried out by using an
ImageQuantTM LAS 4000 instrument (General electric) in the
Snow mode. Band intensities expressed as arbitrary units were
determined using ImageJ software and normalized relative to
the G6Pdh control.
Protein Fractionation and Tau
Localization
Wild-type, pho85, and vip1 mutant cells expressing native human
tau were lysed in ice−cold buffer (50 mM HEPES, pH 7.4, 50 mM
NaCl), and the corresponding protein extracts were centrifuged
at 500 × g for 5 min to remove unbroken cells and glass beads.
The clear supernatants were recentrifuged at 17,900 × g for
10 min. The supernatant (fraction S) was collected, and the
Triton X-100-soluble proteins were extracted by incubating the
pellet on ice for 30 min with the same volume of lysis buffer
that contained 1% Triton X−100 and 0.001% Na+−deoxycholate
(Babu et al., 2012). The extract was recentrifuged, and the
supernatant (fraction S2) was recovered. Finally, the resulting
pellet was resuspended in Laemmli loading buffer, heated at
95◦C for 5 min and centrifuged and the supernatant containing
mostly lipid raft-associated proteins (fraction S3) was recovered.
Likewise, fractions S1 and S2 were mixed with loading buffer and
treated as above before protein assay by SDS-PAGE and Western
blot was conducted.
Sphingolipid Extraction and Mass
Spectrometry Analysis
The cells (∼100 OD600 units) grown in SCD (Abs600 ∼0.5–1.0)
at 30◦C were suspended in 1.5 ml of Mandala extraction buffer
(Mandala et al., 1995) and lipid standards (C17-SpH, C17-DhS,
SpH-1P, and C8-PhS; Avanti Polar Lipids, Alabaster, AL), and
glass beads (1.0 g; acid washed, 0.4 mm diameter) were added.
Then, the mixture was vortexed three times for 1 min each time
and incubated at 60◦C for lipid preparation as described (Singh
et al., 2011, 2012).
For LC-MS, lipid samples were dissolved in 150 µl of
ammonium formate (1 mM) with 0.2% formic acid in methanol
and separated in an Accela HPLC system (Thermo Scientific, San
Jose, CA) coupled to a Spectra C8 (Peeke Scientific, Redwood
city, CA) HPLC column (150 × 3 mm) and the HESI source
of a TSQ Quantum Ultra triple quadrupole mass spectrometer
(Thermo Fisher Scientific). LCBs and their phosphorylated forms
(LCBPs) were analyzed, and the mass spectrometer was operated
as described (Singh et al., 2012). Samples were processed by the
Xcalibur 2.2 Quan Browser software (Thermo Fisher Scientific)
and exported to Excel for reporting results. The levels of the
different lipid species in each sample were normalized to the units
of OD600 processed. All the data were calculated from at least two
biological replicates (±SD).
Determination of Acid Phosphatase
Activity
The phosphatase activity was assayed according to the method
described by Neef and Kladde (2003) with slight modifications.
Briefly, yeast cells were washed twice with water and resuspended
in 0.1 M sodium acetate buffer, pH 4.0 at 4◦C. The reaction was
started by mixing 250 µl of cell suspension, previously incubated
at 30◦C for 5 min, and 250 µl of 20 mM p-nitrophenylphosphate
(Merck KGaA, Darmstadt, Germany Sigma-). After 10 min at
30◦C, the reaction was stopped by adding 125 µl of 1 M Na2CO3
and quantified by measuring the absorbance at 420 nm. Activities
are reported in units per OD600 [(OD420)/(OD600 × volume (in
ml) of cells assayed× 10 min)] and are the mean (±SD) of at least
three independent experiments.
Statistical Analysis
Sample averages were compared using a Student’s t-test with
the Excel software (Microsoft). p < 0.05 (∗,#) was considered
statistically significant.
RESULTS AND DISCUSSION
The Phosphorylation of Tau Depends on
the Cell’s Metabolic State
Different studies have established a link between glucose
energetic hypometabolism and the pathogenesis of AD (Mosconi
et al., 2008; Kapogiannis and Mattson, 2011). Recently, it has also
been reported that IP6K3 variants that increase the production of
DPIP IP7, impact on neuronal energy homeostasis and increase
the risk of sporadic LOAD (Crocco et al., 2016). Accordingly, we
examined the relationship between tau phosphorylation, energy
metabolism, and inositol hexakisphosphate kinases, Kcs1 and
Vip1, in our yeast model system using the CEN.PK2-1C genetic
background. Figure 1A shows a schematic representation of the
metabolic steps and enzymes involved in the synthesis of IPs
and DPIPs in S. cerevisiae and its relationship with the protein
kinase Pho85. First, we analyzed the influence of the growth
phase in the electrophoretic pattern of tau. For this, yeast cells
were transformed with plasmid pYX212-Tau2N/4R (Vandebroek
et al., 2006), which expresses the longest native isoform of tau,
and the transformants were then grown in SCD-Ura medium.
Samples from both actively growing cultures (Abs600 ∼0.5) or
at the stationary phase (overnight cultures), when glucose is
exhausted, were analyzed. The proteins were obtained by alkaline
lysis, separated by SDS-PAGE and further visualized by Western
Blotting using Tau5, a monoclonal antibody that recognizes the
human tau sequence 218–225 independent of its phosphorylation
status, and AD2, which is specific for the phosphorylated
S396/S404 epitopes (Buée-Scherrer et al., 1996), a well-known
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FIGURE 1 | Glucose availability, Pho85, and inositol hexakisphosphate kinases influence tau phosphorylation. (A) Schematic representation of the inositol phosphate
(IP) pathway and its interaction with the Pho80-Pho81-Pho85 complex. The metabolic steps and enzymes involved in the synthesis of IPs and diphosphoinositol
phosphates (DPIPs) are shown (see Dubois et al., 2002; Mulugu et al., 2007; Lin et al., 2009; Wilson et al., 2013 for representative reviews). The hydrolysis of PI(4,
5)P2 by Plc1 generates IP3, which is sequentially phosphorylated to form in the last steps the DPIPs 1-PP-IP5 (1-IP7) and 5-PP-IP5 (5-IP7) through the action of the
inositol hexakisphosphate kinases Vip1 and Kcs1 (IP7 and IP6 kinases, in mammals), respectively. The 1-IP7 isomer acts as an inhibitor of the cyclin-regulated kinase
complex Pho81-Pho80-Pho85 (Lee et al., 2007), which responds to phosphate availability (Lee et al., 2008). The black dot indicates a single phosphate group. The
red dot represents a high-energy phosphate or pyrophosphate. For more details, see text. (B) Transformants of the CEN.PK2-1C wild-type (wt), pho85, kcs1, and
vip1 strains harboring the plasmid pYX212-Tau2N/4R (Vandebroek et al., 2006), which express a native isoform of tau, were grown to the mid-logarithmic phase
(Logarithmic) in SCD-Ura medium at 30◦C. An aliquot of each culture was withdrawn, and the rest was kept under the same conditions until glucose was exhausted
(stationary). Protein extracts were prepared and analyzed by SDS-PAGE and Western blot. Antibodies against human tau sequence 218-225 (Tau5) and
phospho-S396/S404 epitopes (AD2) were used to visualize total and hyperphosphorylated tau, respectively. The abundance of phosphoglycerate kinase 1 (Pgk1)
visualized with anti-Pgk1 was used as loading control. (C) Cell cultures of pYX212-Tau2N/4R transformants of the CEN.PK2-1C wild-type strain were grown until
reaching an Abs600 ∼0.3 in SCD-Ura. Then, an aliquot was processed (control, 0 h) and the rest of the culture was centrifuged. Cells were washed, transferred to
fresh SCD-Ura medium (control), or to the same medium containing 0.01% glucose (glucose) as sole carbon source, grown at 30◦C, and samples were taken at the
indicated times for Western blot analysis of tau isoforms. Total and hyperphosphorylated tau were visualized by using Tau5 and AD2 antibodies, respectively. The
numbers show the AD2 band intensity (±SD) expressed as arbitrary units, which was determined using ImageJ software and normalized relative to the glucose
6-phosphate dehydrogenase control (G6Pdh). Data are the mean (±SD) of three independent experiments. Statistical significance was determined by using a
Student’s t-test with the Excel software (Microsoft). The glucose starvation samples (glucose) were significantly different compared with their respective control at the
same incubation times (*p < 0.05). (D) Pho85-Myc tagged cells of the CEN.PK2-1C wild-type strain were grown at 30◦C in SCD-Ura medium, harvested at the
indicated Abs600 values, and protein extracts were compared for Pho85 abundance by Western blot. An antibody against Myc was used. Representative
experiments are shown.
GSK3β/Mds1 targets (Spittaels et al., 2000; Vandebroek et al.,
2005, 2006). Protein samples from wild-type (wt) and pho85
transformants were used as controls. As shown in Figure 1B,
different electrophoretic bands with apparent molecular weights
varying from 64 to 68 kDa were mainly detected when protein
samples from logarithmic-phase grown cells of the wild-type
strain were analyzed using the Tau5 antibody. These represent
several phospho-forms of tau. In comparison, samples from
the pho85 mutant showed an additional lower mobility band
with an apparent molecular weight of approximately 72 kDa
that corresponds to hyperphosphorylated tau (Vandebroek et al.,
2005; Vanhelmont et al., 2010). The latter is also readily
detected using the AD2 antibody (Figure 1B). It has been
described that Pho85/CDK5, exerts its function by inhibiting
the downstream kinases Mds1/GSK3β, the reason why deletion
of PHO85 leads to hyperphosphorylation of tau (Vandebroek
et al., 2006; Vanhelmont et al., 2010). As expected, logarithmic-
grown cells of the kcs1 mutant, which shows increased levels
of 1-IP7 (Ye et al., 2013; Córcoles-Sáez et al., 2016) and
thus a lower activity of the Pho80-Pho85 kinase complex
(Lee et al., 2007), displayed a similar profile of bands as the
pho85 mutant. However, protein extracts from vip1 cells, which
produce the isomer 5-IP7 instead of 1-IP7 (see Figure 1A),
also exhibited a strong lower mobility band revealed by
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either Tau5 or AD2 antibodies (Figure 1B). It is worth
mentioning that unlike 1-IP7, the 5-IP7 isomer has no apparent
inhibitory effect on the Pho80-Pho85 kinase complex activity
(Lee et al., 2007).
Concerning stationary-phase-grown cells, glucose starvation
rendered tau more susceptible to hyperphosphorylation
(Figure 1B). Indeed, while there was an evident reduction
in the overall expression of tau in the overnight cultured
wild-type cells as judged from the intensity of the Tau5 signal,
both Tau5, and AD2 readily detected the lowest mobility band
that corresponds to hyperphosphorylated tau (Figure 1B).
Consistently, enhanced tau hyperphosphorylation was also
evident in the protein extracts of overnight cultures from the
pho85, the kcs1, and the vip1 strains (Figure 1B). Moreover,
SCD-Ura-grown wild-type cells transferred from high (2%) to
low glucose (0.01%) medium recapitulated the changes of tau
isoforms observed at the stationary phase of growth (Figure 1C).
Finally, the enhanced hyperphosphorylation of tau after the
logarithmic-phase yeast growth coincided with the gradual
decline of Pho85 abundance, as evidenced by Western blot
analysis of wild-type cells harboring a Myc-tagged version of
the Pho85 protein kinase (Figure 1D). Hence, these changes
could be mediated by energy-dependent regulations of Pho85,
and likely other protein kinases, by DPIPs. Notably, the deficit
in glucose availability in the humanized yeast model thereby
seems to mimic the dysregulation of CDK5 (Wu et al., 2000)
and increased tau phosphorylation as seen in aging brain
(Kelleher et al., 2007).
Hyperphosphorylation of Tau Has No
Major Effect on Yeast Growth but
Changes Its Membrane Association
Previous studies indicated that human tau expressed in yeast
cells does not affect the growth rate (Vandebroek et al., 2005).
We analyzed whether hyperphosphorylation of tau by lack of
Pho85, Kcs1, or Vip1 could contribute to increase tau toxicity
in our yeast model. As shown in Supplementary Figure S1,
the wild-type, pho85, kcs1, or vip1 strains transformed with
either pYX212-Tau2N/4R or the empty vector control displayed a
similar behavior when growth was examined in liquid SCD-Ura,
indicative that the expression of tau has no significant impact on
the viability of these strains.
Next, we analyzed if the enrichment of hyperphosphorylated
tau isoforms alters the cellular distribution of the protein in
yeast cells. Several studies indicated tau to interact with the
plasma membrane and endomembranes (Elbaum-Garfinkle et al.,
2010; Georgieva et al., 2014). Moreover, it has been shown that
hyperphosphorylation of tau in, among others, S396/S404 residues
completely abolish tau’s association with the membrane (Maas
et al., 2000). We examined the electrophoretic profile of tau
in soluble and membrane-enriched fractions of crude protein
extracts from logarithmic-grown wild-type, pho85, and vip1 cells.
Three fractions, corresponding to cytosolic soluble proteins (S1),
Triton X-100-soluble proteins (S2), and Triton X-100-insoluble
proteins (S3), were analyzed by SDS-PAGE and Western blot
(Figure 2). As shown, the profile of bands observed with Tau5
and AD2 antibodies differed between these fractions. The tau
protein was mainly localized in the yeast plasma membrane, and
in particular in the Triton X-100-insoluble fraction (S3), which
was solubilized with SDS (Figure 2; left graph). Only in the vip1
strain, the soluble S1 fraction contained a higher amount of total
tau, which is likely due to hyperphosphorylation as revealed in
the AD2 signal (Figure 2). Indeed, the ratio of AD2/Tau5 signals
(Figure 2; right graph) clearly indicates that phosphorylation of
tau at its AD2 epitope decreases the association of the protein
with the yeast plasma membrane.
Pho85 and Inositol Hexakisphosphate
Kinases Influence the Phosphorylation of
Tau-S409
The results described above confirmed the role of Pho85,
Kcs1, and Vip1 in regulating the Mds1/GSK3β-dependent
phosphorylation of S396/S404 at the AD2 epitope of tau. At
this point, we wondered if this functional interaction extends
to other tau kinases. Previous work has demonstrated a link
between phosphorylation of S396/S404 and S409, a target of
PKA (Terwel et al., 2005; Vandebroek et al., 2006) that is
crucial for tau aggregation in yeast (Vanhelmont et al., 2010).
Since it was then shown that the clinical mutant tau-R406W
is hampered for phosphorylation S396/S404 and S409, we also
expressed this clinical tau mutant in the wild-type, pho85,
kcs1, and vip1 strains. Western blot analysis confirmed that
the 72-kDa low mobility band as visualized with either Tau5
or more clearly with the AD2 antibody is only weakly present
upon expression of native wild-type tau but completely absent
upon expression of the mutant tau-R406W in wild-type cells
(Figure 3). However, the lack of Pho85 activity still increased the
S396/S404 hyperphosphorylation of both wild-type tau and tau-
R406W (Figure 3). Also, cells lacking Kcs1 or Vip1 displayed
higher levels of the hyperphosphorylated 72 kDa isoform upon
expression of wild-type tau, although only the mutation of
KCS1 produced a statistically significant positive effect on tau-
R409W (Figure 3; AD2 image and graph). To further confirm
these results, protein samples from all the abovementioned
transformants were prepared again and tau was visualized with
PG5, a phospho-specific antibody that recognizes the phospho-
S409 epitope. As expected, lack of either Pho85, Kcs1, or Vip1
stimulated not only the phosphorylation of S396/S404 but also
of S409 (Figure 3; PG5 image and graph). We conclude that
Pho85, Kcs1, and Vip1 contribute to tau phosphorylation by
different kinases.
The IP Pathway Plays a Role in Tau
Phosphorylation
We next examined whether the role of inositol hexakisphoshate
kinases Kcs1 and Vip1 in modulating tau phosphorylation
extends to upstream kinases Ipk2 and Ipk1, and Plc1, the yeast
phospholipase (Figure 1A). As compared with the wild type,
knockout of IPK1, which interrupts the IP pathway at the IP5
level, decreased the abundance of total tau (Figure 4A; Tau5
image), although its phosphorylation level was not apparently
affected (Figure 4A; AD2 image). On the contrary, lack of
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FIGURE 2 | tau localization is influenced by its phosphorylation. Transformants of the CEN.PK2-1C wild-type (wt), pho85 and vip1 mutant strains expressing native
tau (pYX212-Tau2N/4R) were grown until reaching an Abs600 ∼0.3 in SCD-Ura. Protein extracts were processed, fractionated, and analyzed as described in the
“Materials and Methods” section. Three fractions, soluble proteins (S1), Triton X-100-soluble proteins (S2), and Triton X-100-insoluble proteins (S3) were analyzed for
total and hyperphosphorylated (phospho-S396/S404 epitopes) tau isoforms by using Tau5 and AD2 antibodies, respectively. The graphs show the relative abundance
(%) of total tau (left panel) and the ratio between AD2 and total tau (AD2/Tau5; right panel) for each strain and protein fraction. Band intensities were determined
using ImageJ software and normalized relative to the glucose 6-phosphate dehydrogenase control (G6Pdh). Total tau was estimated as the sum of band intensities
of tau isoforms with apparent molecular weights varying from 64 to 72 kDa. Data are the mean (±SD) of three independent experiments. Statistical significance
(∗p < 0.05) was determined for S3 sample averages compared with S1 sample averages of each strain. Representative Western blot images are shown.
Ipk2, the enzyme that converts IP3 into IP5, or PLC1 that
completely abolish IP and DPIP synthesis (Figure 1A), resulted
in increased levels of the hyperphosphorylated 72 kDa isoform of
tau (Figure 4A).
Then, we analyzed if the effect on tau phosphorylation
observed in the plc1, ipk2, and vip1 mutants could be explained
as a result of the inactivation of Pho85. All of these strains
share in common to make no 1-IP7, while kcs1 shows enhanced
levels of the DPIP isomer (Ye et al., 2013; Córcoles-Sáez
et al., 2016). Nevertheless, IP4 and/or IP5, and Plc1, also
play a role in regulating the transcription of some Pho85-
dependent genes, although strain-dependent discrepancies have
been reported (Steger et al., 2003; Auesukaree et al., 2005;
Prieto et al., 2020). To clarify this point in the CEN.PK2-
1C yeast background, we first assayed the activity of the
Pho85-repressed acid phosphatase Pho5 in SCD-grown cells
(Figure 4B). As expected, Pho5 activity was fully dysregulated
in cells of the pho85 mutant. Compared with this, lack of
Kcs1, but also of Ipk2 and Plc1 caused a partial dysregulation.
On the contrary, no effect could be detected by deletion of
VIP1 (Figure 4B). Neither the mutation of IPK1 caused the
upregulation of Pho5 activity. To further confirm these results,
we compared the abundance of the cyclin-dependent kinase
(CDK) inhibitor Pho81, which downregulates the activity of
the Pho80-Pho85 complex, in wild-type, kcs1, vip1, and plc1
yeast strains. As it is shown in Figure 4C, transfer of wild-
type cells from high phosphate to starvation medium stimulated
the synthesis of Pho81. As for Pho5 activity, lack of Kcs1
dysregulated the expression of Pho81 and high levels of the
protein could be detected even in high-phosphate conditions,
a similar result to that observed for pho85 mutant cells (data
not shown). Likewise, the PLC1 deletion also stimulated the
synthesis of Pho81, while vip1 cells were insensitive to phosphate
starvation (Figure 4C). Hence, our results provide evidence of
the involvement of the IP pathway in the regulation of tau
phosphorylation. Thereby, changes in 1-IP7 levels are certainly
critical to modulate the activity of Pho85, but additional
mechanisms have to be evoked to fully explain the functional
link between elements of the IP pathway, like Vip1, and tau
phosphorylation.
Interplay Between Sphingolipids and Tau
Hyperphosphorylation
The IP pathway is networked with other important cellular
signaling pathways (Huang and O’Shea, 2005) and lipid
metabolic routes (Córcoles-Sáez et al., 2016; Prieto et al., 2020)
that could represent additional points of tau regulation. In
particular, Pho85 has been identified as playing a key role in
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FIGURE 3 | Pho85, Kcs1 and Vip1 contribute to tau phosphorylation by different kinases. Native wild-type tau (N) and the clinical R406W tau mutant (Vanhelmont
et al., 2010) were expressed in wild-type (wt), pho85, kcs1, and vip1 strains, and the electrophoretic profile of the protein from logarithmic-SCD-Ura-grown (Abs600
∼0.3) cells was analyzed by Western blot using Tau5 and phospho-specific antibodies against S396/S404 (AD2) and S409 (PG5) epitopes. The graphs show the AD2
and PG5 band intensities (±SD) expressed as arbitrary units. Protein extraction, band intensity determination, and statistical analysis were as described in
Figure 1C. Data are the mean (±SD) of three independent experiments. *p < 0.05 for AD2 or PG5 band intensity of the mutant strains compared with AD2 or PG5
band intensity of the wild-type control strain. Representative Western blots images are shown.
FIGURE 4 | Tau phosphorylation is regulated by IP signaling by Pho85-dependent and Pho85-independent mechanisms. (A) Protein extracts from SCD-grown
cultures of wild-type (wt), plc1, ipk2, and ipk1 transformants of the CEN.PK2-1C yeast background, which express a native isoform of tau, were analyzed by
Western blot using Tau5 and AD2 antibodies. The numbers show the AD2 band intensity (±SD) expressed as arbitrary units. Quantification was carried out as in
Figure 1C. Data are the mean (±SD) of three independent experiments. *p < 0.05 for AD2 band intensitiy of the mutant strains compared with AD2 band intensity
of the wild-type control strain. (B) The activity of the Pho85-repressible acid phosphatase Pho5 (units/OD600) was measured in protein extracts from
logarithmic-SCD-Ura-grown (Abs600 ∼0.3–0.5) cultures. Cells of the wild-type (wt), plc1, ipk2, ipk1, vip1, kcs1, and pho85 mutants were analyzed. Data represent
the mean value (±SD) of three independent experiments. *p < 0.05 for Pho5 activity of the mutant strains compared with the Pho5 activity of the wild-type control
strain. (C) The abundance of Pho81 in Pho81-HA-tagged cells of the CEN.PK2-1C wild-type, vip1, kcs1, and plc1 mutant strains was measured before and after
transfer for 3 h of yeast cells from high-phosphate (H Pi) to phosphate-free medium (-Pi). Antibodies against HA and glucose-6-phosphate dehydrogenase (G6Pdh;
loading control) were used. A representative experiment is shown.
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FIGURE 5 | Dysregulated SLs biosynthesis alters the tau electrophoretic profile. (A) Schematic representation showing the initial steps of the SLs biosynthesis from
the rate-limiting step catalyzed by the serine palmitoyltransferase (SPT) complex to ceramide synthase (Lag1, Lac1), and the LCBs-to-glycerophospholipid metabolic
pathway. Orm2 acts as an inhibitor of SPT. LCBs-kinases (Lcb4, Lcb5) use DhS and PhS, the precursors of ceramide (Cer), to form their corresponding
phosphorylated forms DhS-1P and PhS-1P. Details about each step, and the enzymes, effectors and regulators involved, can be found in the text and recent reviews
(Gururaj et al., 2013; Megyeri et al., 2016; Teixeira and Costa, 2016; Roelants et al., 2017). (B) The cells of the CEN.PK2-1C wild-type and its corresponding kcs1
and vip1 mutant strains were grown in SCD medium at 30 ◦C until the mid-logarithmic phase (Abs600 ∼0.5). Lipids were extracted, and the LCBs and LCBPs levels
were analyzed by mass spectrometry as described in the “Materials and Methods” section. Data are the mean (±SD) of two independent biological replicates.
Statistically significant differences (*p < 0.05) between the wild-type and mutant strains are indicated. (C) Cells of the CEN.PK2-1C wild-type strain grown in
SCD-Ura medium lacking (C) or transferred for 1 h to the same medium containing 2 µM myriocin (Myr) or 0.068 µM aureobasidin A (AbA) were examined for tau
isoforms by Western blot of protein extracts. Cells exposed for 30 min to external 25 µM phytosphingosine (PhS) were also analyzed. Tau5, AD2, and PG5
antibodies were used to visualize total and hyperphosphorylated tau, respectively. An inespecific PG5 signal is indicated with an arrow. Quantification of band
intensities was carried out as described in Figure 1C. Data represent the mean value (±SD) of three independent experiments. Statistically significant differences
(*p < 0.05) between control and treatment samples are indicated. (D) The electrophoretic pattern of tau from pYX212-Tau2N/4R transformants of the BY4741
wild-type (wt), fpk1 fpk2 (fpk1/2), and ypk1 strains grown in SCD-Ura medium were analyzed as in (C). Representative Western blot images are shown.
controlling the synthesis of LCBs and LCBPs via the Ypk1-Orm2
regulatory circuit (Prieto et al., 2020) and the LCB-kinase Lcb4
(Iwaki et al., 2005; see Figure 5A for a representation of the
SL pathway). Thus, pho85 mutant cells present a unique profile
of complex SLs (da Silveira Dos Santos et al., 2014), decreased
LCB content, and accumulation of LCBPs (Prieto et al., 2020).
These evidences led us to examine the presence of sphingoid
bases in the inositol hexakisphosphate kinase mutant kcs1 and
vip1. As it is shown in Figure 5B, DhS and PhS levels from
kcs1 and vip1 mutant cells were almost identical to those of
the wild type. Only the amount of PhS was slightly reduced
in the vip1 strain (Figure 5B). Compared with this, both
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mutants displayed an important variation in their content of
phosphorylated sphingoid bases. The DhS-1P level increased
fourfold in kcs1 cells, and remarkably, the amount of DhS-1P
and PhS-1P raised two- and threefold, respectively, in the vip1
mutant (Figure 5B).
Then, we analyzed the electrophoretic profile of tau in
cells treated with PhS, the main LCB subclass in yeast
(Figure 5B), Myr, or AbA. Myr is an inhibitor of SPT
(Miyake et al., 1995), the enzymatic complex that catalyzes
the first step in the SL biosynthesis pathway (Hanada, 2003;
Figure 5A), and thus, myriocin treatment reduces the carbon
flux through the pathway (Han et al., 2010), decreasing the
content of LCBs/LCBPs and complex SLs (Huang et al.,
2012). AbA treatment inhibits the activity of Aur1, the first
enzyme involved in the synthesis of complex SLs, which
results in increased amounts of ceramides but lower complex
SLs (Nagiec et al., 1997). As shown in Figure 5C, treatment
of wild-type yeast cells with AbA had no major effect on
the abundance of hyperphosphorylated tau. However, addition
of Myr to the yeast culture increased the abundance of
hyperphosphorylated tau isoforms visualized with Tau5, AD2,
or PG5 antibodies (Figure 5C), indicating that a defective
SL pathway stimulates tau phosphorylation. On the contrary,
increased LCBs by adding external PhS reduced the abundance
of both phospho-S396/S404 (Figure 5C; AD2) and phospho-S409
tau (Figure 5C; PG5).
Finally, we examined the tau phosphorylation profile in
yeast mutants lacking kinases involved in the regulation of
the SL synthesis. In particular, we paid special attention to
the behavior of tau in cells lacking Ypk1 and Fpk1,2. The
protein kinase Ypk1 stimulates the SL synthesis by inhibiting
the activity of Orm2 (Breslow et al., 2010; Roelants et al.,
2011), a negative regulator of SPT (Figure 5A). On the other
hand, the homologous protein kinases Fpk1,2 inhibit Ypk1 by
phosphorylation, which depresses the SPT activity by increasing
the inhibition mediated by Orm2 (Roelants et al., 2010). Thus,
lack of Ypk1 and Fpk1,2 reduces and increases, respectively,
the SPT-catalyzed synthesis of LCBs and, consequently, the flux
through the SL-biosynthesis pathway (Figure 5A). As shown
in Figure 5D, the loss of Ypk1 activity increased slightly the
hyperphosphorylation of tau as compared with wild-type cells,
although the differences were not statistically significant. It is
FIGURE 6 | The Sit4 protein phosphatase is a SL-downstream target in regulating tau phosphorylation. (A) The tau isoforms from pYX212-Tau2N/4R transformants
of the BY4741 wild-type (wt), pho85, lcb3, lcb4, and lcb5 mutant strains grown in SCD-Ura medium were analyzed by Western blot as described in Figure 1C. Data
represent the mean value (±SD) of three independent experiments. Statistically significant differences (p < 0.05) between mutant strains and the wild-type control
strain are indicated (*). (B) Proteins extracts from logarithmic-grown cultures of pYX212-Tau2N/4R transformants of the CEN.PK2-1C wild-type (wt) strain, sit4, sit4
lcb4, and sit4 lcb5 were analyzed as in (A). (C) Cells of the same strains were examined for growth in YPD lacking or containing 0.068 µM aureobasidin A
(YPD+AbA). Overnight YPD-grown cultures were adjusted to Abs600 ∼0.5, diluted (1–10−3), spotted (3 µl) onto the mentioned media, and incubated at 30◦C for
2–5 days. A representative experiment is shown.
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worth noting that Ypk1 share an extensive homology with a
redundant protein kinase Ypk2, and that cells lacking both
Ypk1 and Ypk2 are inviable (Chen et al., 1993). Contrastingly,
the simultaneous disruption of FPK1 and its homolog FPK2,
the two protein kinases that mediate the negative regulation of
Ypk1 (Figure 5A), caused a clear and significant reduction of
tau hyperphosphorylation (Figure 5D). Altogether, our results
strongly support a role of the SL metabolism in regulating tau
hyperphosphorylation.
The Ceramide-Regulated Protein
Phosphatase Sit4 Plays a Major Role in
Tau’s Dephosphorylation
The LCB kinases and phosphatases play an important role in
regulating the irreversible degradation of LCBs to ethanolamine-
phosphate and C16-aldehydes, and consequently, their activity
modulate the carbon flux through the SL biosynthesis pathway
(Figure 5A). On the other hand, Sit4, a ceramide-activated
protein phosphatase, is the yeast ortholog of human PP2A, which
is involved in the dephosphorylation of tau (Sontag and Sontag,
2014; Taleski and Sontag, 2018). Thus, Sit4 could be a key element
in connecting SL metabolism and tau hyperphosphorylation,
but no evidence of this function in humanized yeast has
been reported yet.
Here, we first inspected the profile of the tau phospho-
isoforms by visualization with Tau5 and AD2 antibodies in cells
of the lcb3, lcb4, and lcb5 mutants, using samples from the
wild-type and pho85 strains as control (Figure 6A). Like pho85
cells, absence of Lcb3-mediated LCBP-phosphatase activity,
which favors the degradation of LCBs, increased slightly the
intensity of the 72-kDa low mobility tau band visualized with
AD2, but the change was not significant. In contrast, reducing
LCB-kinase activity by deleting of either LCB4 and LCB5
resulted in a reduced abundance of this hyperphosphorylated tau
isophorm (Figure 6A).
Then, we examined whether these changes might be related
with the activity of Sit4 and whether the mutation of SIT4
affects the tau phospho-isoform profile. Indeed, protein samples
isolated from sit4 cells appeared to contain a higher fraction
of hyperphosphorylated tau (Figure 6B). Interestingly, the
additional mutation of LCB4 or LCB5 in the sit4 background,
did not affect the tau pattern observed in the sit4 mutant
strain (Figure 6B), indicating that Sit4 is placed downstream
of the LCB kinases. To further confirm this point, we checked
the phenotype of all these mutants in YPD plates containing
AbA (Figure 6C). As indicated, AbA exposure increases the
level of ceramides, a well-known inducer of apoptosis and cell
death (Hannun and Obeid, 2011), and thus, AbA sensitivity
is an indirect way to estimate the cell’s content of this
lipid class. As shown, the lcb4 and lcb5 single mutant cells
exhibited strong sensitivity to the drug, indicating higher
ceramide levels than the wild type (Figure 6C). Cells lacking
Sit4 activity showed a slight defect of growth, consistent with
the multiple regulatory roles of the protein phosphatase in
different metabolic processes (Vilaça et al., 2018), but again,
the absence of Sit4 supressed the phenotype of lcb4 and lcb5
mutant strains (Figure 6C). A positive effect of the lack of
Sit4, in particular for the double sit4 lcb5 mutant, was also
observed when the growth was monitored in YPD liquid
medium lacking or containing AbA at different concentrations
(Supplementary Figure S2).
CONCLUDING REMARKS
In the last years, increasing evidence supports the hypothesis
that dysregulated energy and lipid metabolism could be
a key mechanism contributing to the pathogenesis of
neurodegenerative disorders. Here, we show for the first
time that changes in the IP signaling, which act as an energy
sensor, promote molecular alterations underlying tauopathies.
This is in good agreement with recent research showing that
dysregulation of IP6K gene contributes to LOAD (Crocco
et al., 2016). Defects in this metabolism affect the activity
of Pho85, the yeast ortholog of CDK5, which could explain
the strong phosphorylation of tau found in some mutants
of the pathway, such as kcs1. In this context, the finding
that avoiding the synthesis of 1-IP7 by deletion of PLC1,
IPK1, or VIP1 also results in tau hyperphosphorylation adds
complexity to the tau regulation and suggests the existence
of Pho85-independent mechanisms that requires further
investigation. A better understanding of the networking
operating between the IP pathway and other lipid pathways will
support further the development of IP-targeted molecules in
therapeutic approaches.
Interestingly, vip1 and kcs1 mutant cells showed a strong
accumulation of LCBPs, suggesting an aberrant SLs metabolism
by dysregulation of the IPs pathway. Consistent with this, we
showed by genetic and drug-treatment approaches that inhibiting
the SLs pathway stimulates the hyperphosphorylation of tau,
while the opposite effect is observed by increasing SLs synthesis.
Moreover, we found that Sit4, the yeast ortholog of PP2A and
ceramide-activated protein phosphatase, is a downstream target
of SLs signaling that impacts on tau phosphorylation. Changes
in SLs metabolism are a hallmark of different neurodegenerative
disorders, including AD (Alaamery et al., 2020; Crivelli et al.,
2020), and drugs targeting S1P and its receptors (O’Sullivan
and Dev, 2017) or lowering ceramide levels (Brodowicz et al.,
2018) have been claimed as potentially useful for the treatment
of AD. However, studies on sphingosine kinase and sphingosine-
degrading enzymes have shown that lowering sphingosine kinase
2 (SK2) activity and S1P levels decreases the Aβ production
in vitro and in vivo (Takasugi et al., 2011; Karaca et al.,
2014; Lei et al., 2019). In this scenario, our study adds new
knowledge on the effectors and molecular events that linked
SLs and tau phosphorylation. Taking into account the diversity
of SLs functions and the complexity and interdependency
of signals they generate, the yeast model can be exploited
to speed up the advances in the field of AD and other
neurodegenerative diseases as to provide putative novel targets
for therapeutic intervention.
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